Clinical features of patients according to relapse frequency
| Demographics . | Frequent relapses (n = 28) . | Infrequent relapses (n = 103) . | P . |
|---|---|---|---|
| Duration of follow-up (IQR), y | 7.8 (4.4-9.5) | 9.1 (6.5-11.1) | .02 |
| Age at initial presentation, y (range) | 48.9 (38.4-53.2) | 44.0 (32.8-54.3) | .36 |
| Age <25 y at presentation, n (%) | 2 (7.1) | 9 (8.7) | .27 |
| Gender (male/female), n (%) | 9 (32.1)/19 (67.9) | 34 (33.0)/69 (67.0) | .93 |
| Ethnicity, n (%) | <.001 | ||
| Caucasian | 13 (46) | 56 (54) | |
| Black African | 5 (17) | 7 (7) | |
| Black Caribbean | 6 (21) | 11 (11) | |
| Asian | 2 (7) | 12 (12) | |
| Mixed | 1 (4) | 3 (3) | |
| Other | 1 (4) | 2 (2) | |
| Unknown | 0 (0) | 6 (6) | |
| Treatment at acute presentation, n (%) | |||
| Corticosteroid | 24 (86) | 86 (83) | |
| Rituximab | 16 (57) | 60 (58) | |
| Mycophenolate mofetil | 0 (0) | 1 (1) | |
| Caplacizumab | 0 (0) | 3 (3) |
| Demographics . | Frequent relapses (n = 28) . | Infrequent relapses (n = 103) . | P . |
|---|---|---|---|
| Duration of follow-up (IQR), y | 7.8 (4.4-9.5) | 9.1 (6.5-11.1) | .02 |
| Age at initial presentation, y (range) | 48.9 (38.4-53.2) | 44.0 (32.8-54.3) | .36 |
| Age <25 y at presentation, n (%) | 2 (7.1) | 9 (8.7) | .27 |
| Gender (male/female), n (%) | 9 (32.1)/19 (67.9) | 34 (33.0)/69 (67.0) | .93 |
| Ethnicity, n (%) | <.001 | ||
| Caucasian | 13 (46) | 56 (54) | |
| Black African | 5 (17) | 7 (7) | |
| Black Caribbean | 6 (21) | 11 (11) | |
| Asian | 2 (7) | 12 (12) | |
| Mixed | 1 (4) | 3 (3) | |
| Other | 1 (4) | 2 (2) | |
| Unknown | 0 (0) | 6 (6) | |
| Treatment at acute presentation, n (%) | |||
| Corticosteroid | 24 (86) | 86 (83) | |
| Rituximab | 16 (57) | 60 (58) | |
| Mycophenolate mofetil | 0 (0) | 1 (1) | |
| Caplacizumab | 0 (0) | 3 (3) |